Research programme: thorium-227 radiolabelled antibodies - Bayer/ProgenicsAlternative Names: 1095 - Bayer/Progenics; MIP 1095 I-131; PSMA targeted therapeutics; PSMA-ADC
Latest Information Update: 16 May 2016
At a glance
- Originator Bayer
- Class Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Prostate cancer